Key result
Chemotherapy including paclitaxel enabled a patient with metastatic primary splenic angiosarcoma to survive for approximately 2 years, compared to a median overall survival of 105 days in historical stage IV cases.
Why the study?
Primary splenic angiosarcoma is a rare soft tissue sarcoma associated with an extremely poor prognosis.
Does chemotherapy including paclitaxel improve survival in patients with metastatic primary splenic angiosarcoma?
Case Report (n=1)
Does chemotherapy including paclitaxel improve survival in patients with metastatic primary splenic angiosarcoma?
Chemotherapy including paclitaxel may improve prognosis in patients with metastatic primary splenic angiosarcoma.
Should not change management of metastatic splenic angiosarcoma; leaves open paclitaxel role in prospective trials.
A primary splenic angiosarcoma is a rare type of soft tissue sarcoma and is associated with an extremely poor prognosis. In this study, we describe the case of a patient who was diagnosed with metastatic primary splenic angiosarcoma and survived for about 2 years. A 62-year-old female was referred to us for the treatment of splenic angiosarcoma with disseminated intravascular coagulation (DIC) and multiple liver and bone metastases. Paclitaxel therapy resulted in recovery from DIC and enabled her to continue sequential treatment through to sixth-line chemotherapy. We reviewed all splenic angiosarcoma case reports which were described as stage IV to date and compared with our case. From these data, we found that the median overall survival was 105 days, and the prognosis of splenic angiosarcoma of stage IV was worse than conventional case series. Splenectomy was performed in more patients than chemotherapy as a treatment. Moreover, various chemotherapeutic regimens were used. These data suggest that administering chemotherapy including paclitaxel to patients with splenic angiosarcoma might improve their prognosis.
No takes yet. Share an insight, caveat, or question.
Takehara et al. (2021) conducted a case report in Metastatic primary splenic angiosarcoma (n=1). Chemotherapy including paclitaxel vs. Conventional case series was evaluated on Overall survival. Chemotherapy including paclitaxel enabled a patient with metastatic primary splenic angiosarcoma to survive for approximately 2 years, compared to a median overall survival of 105 days in historical stage IV cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: